Japan headquartered Takeda Pharmaceutical Company Limited recentky hosted an R&D meeting in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is expected to drive the company’s near-term and sustained growth.

In the near-term, Takeda expects that its 14 current global growth brands will generate significant momentum enabled by at least 20 additional indications and major market expansions through FY24.

In the same time period, the organization anticipates delivering 12 new molecular entities with the potential for 14 launches, representing best-in-class or first-in-class therapies across its core areas of focus.

Looking ahead to FY25 and beyond, Takeda’s transformative R&D engine comprising internal research capabilities and external partnerships is expected to advance a steady stream of next-generation therapies based on human validated targets, diverse modalities, and new platform capabilities, including those in cell therapy, gene therapy and data sciences.